MedTrace Logo

NAC for Treating Comorbid PTSD and SUD

NCT02911285 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2021-05-19

Study results available
· View outcomes & findings →

Summary

As a result of sustained operations in Afghanistan and Iraq, there are an increasing number of U.S. military Veterans with substance use disorders and comorbid posttraumatic stress disorder (PTSD). If left untreated, individuals with substance use disorders and PTSD are at increased risk for developing other mental health problems (e.g., depression, anxiety), suicidal ideation and attempts, medical problems, reduced resiliency and military readiness, vocational problems, and family/social impairment. This study will determine the benefits of N-acetylcysteine (NAC) in treating alcohol use disorder and comorbid post-traumatic stress disorder (PTSD) among military Veterans.

Conditions

  • Posttraumatic Stress Disorder (PTSD)
  • Alcohol Use Disorder (AUD)
  • Substance Use Disorder (SUD)

Interventions

DRUG

N-acetylcysteine

1200mg bid (2400mg/day)

DRUG

Placebo

Placebo pills bid

BEHAVIORAL

Cognitive behavioral therapy

CBT for AUD/SUD, one hour/once a week

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Institute for Translational Neuroscience

    collaborator UNKNOWN

  • Medical University of South Carolina

    lead OTHER

Principal Investigators

  • Sudie Back, Ph.D. · Medical University of South Carolina

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2019-08-05
Completion
2019-11-04

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02911285 on ClinicalTrials.gov